Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04377360 · ClinicalTrials.gov registry record · NA

Feasibility Trial of Diffusing Alpha-emitter Radiation Therapy (DaRT) for Malignant Skin & Superficial Soft Tissue Tumors

A NA study, sponsored by Alpha Tau Medical.

Completed
Registry status
NA
Development phase
10
Enrollment target

NCT04377360 is a NA study that has completed, run by Alpha Tau Medical. The registered enrollment target is 10 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04377360, a NA study, has completed, sponsored by Alpha Tau Medical.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target

Study Summary

This is a single-institution pilot feasibility trial in which 10 subjects will be enrolled. The primary objectives are is to explore the feasibility of delivering radiotherapy for malignant skin and superficial soft tissue tumors using DaRT (Alpha Tau Medical, Tel Aviv, Israel), a form of interstitial brachytherapy which uses a novel radioisotope delivery system, as well as to determine the frequency and severity of acute adverse events. Secondary objectives will include assessments of radiotherapy-related adverse events, tumor response, radiation safety, stability of device placement, and associations with quality of life.

Interventions

  • RADIATION Diffusing Alpha-emitter Radiation Therapy

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2020-01-06
Est. Completion 2022-03-28
Phase NA

Sponsor

Alpha Tau Medical

5 total trials

What the Registry Record Tells You About NCT04377360

The ClinicalTrials.gov registry entry for NCT04377360 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alpha Tau Medical, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Diffusing Alpha-emitter Radiation Therapy is the first listed.

NCT04377360 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04377360 about?

NCT04377360 is a clinical study titled "Feasibility Trial of Diffusing Alpha-emitter Radiation Therapy (DaRT) for Malignant Skin & Superficial Soft Tissue Tumors". This is a single-institution pilot feasibility trial in which 10 subjects will be enrolled. The primary objectives are is to explore the feasibility of delivering radiotherapy for malignant skin and superficial soft tissue tumors using DaRT (Alpha Tau Medical, Tel Aviv, Israel), a form of interstiti...

What is the current status of trial NCT04377360?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2020-01-06. Estimated completion is 2022-03-28.

What interventions are being tested in trial NCT04377360?

The interventions under investigation include: Diffusing Alpha-emitter Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT04377360?

This trial is sponsored by Alpha Tau Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.